Log in

Evofem Biosciences Stock Forecast, Price & News

+0.04 (+1.89 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $2.16
50-Day Range
MA: $2.92
52-Week Range
Now: $2.16
Volume4.00 million shs
Average Volume2.52 million shs
Market Capitalization$175.56 million
P/E RatioN/A
Dividend YieldN/A
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Read More
Evofem Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EVFM



Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share


Net Income$-80,030,000.00


Market Cap$175.56 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
+0.04 (+1.89 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

How has Evofem Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVFM shares have decreased by 58.1% and is now trading at $2.16.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Evofem Biosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evofem Biosciences

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Evofem Biosciences

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.54.
View Evofem Biosciences' earnings history

What price target have analysts set for EVFM?

6 brokers have issued 1 year target prices for Evofem Biosciences' stock. Their forecasts range from $3.00 to $25.00. On average, they anticipate Evofem Biosciences' share price to reach $10.50 in the next year. This suggests a possible upside of 386.1% from the stock's current price.
View analysts' price targets for Evofem Biosciences

Are investors shorting Evofem Biosciences?

Evofem Biosciences saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 5,440,000 shares, an increase of 48.2% from the August 15th total of 3,670,000 shares. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is presently 1.3 days.
View Evofem Biosciences' Short Interest

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), BioNano Genomics (BNGO), Zosano Pharma (ZSAN), AEterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer (Age 49)
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Jason Abrams, Accounting Mang.
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Marshall Wace LLP (4.74%), Heartland Advisors Inc. (3.02%), Hound Partners LLC (1.10%), Prosight Management LP (0.83%), Tudor Investment Corp Et Al (0.52%) and SG Americas Securities LLC (0.44%). Company insiders that own Evofem Biosciences stock include Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences

Which institutional investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC. Company insiders that have sold Evofem Biosciences company stock in the last year include Justin J File, Kelly Culwell, Ltd Invesco, Russell Barrans, and Saundra L Pelletier.
View insider buying and selling activity for Evofem Biosciences

Which institutional investors are buying Evofem Biosciences stock?

EVFM stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Hound Partners LLC, Heartland Advisors Inc., Prosight Management LP, Tudor Investment Corp Et Al, SG Americas Securities LLC, Nuveen Asset Management LLC, and California Public Employees Retirement System. Company insiders that have bought Evofem Biosciences stock in the last two years include Justin J File, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, and William Walmsley Hall.
View insider buying and selling activity for Evofem Biosciences

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $2.16.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $175.56 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is www.evofem.com.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.